{
    "nctId": "NCT06624020",
    "briefTitle": "A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia",
    "officialTitle": "Characteristics and Real-world Use of Palbociclib and Other CDK4/6is in Naive Patients in Australia: a Retrospective Analysis (ROSIE)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1128,
    "primaryOutcomeMeasure": "Demographic characteristic of participants (CDK4/6i cohort): year of birth",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years or older when first received CDK4/6i breast cancer treatment\n* Patient who has received CDK4/6i during study period\n\nExclusion Criteria:\n\n* There are no exclusion criteria for this study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}